Glucocorticoid
Drug
Celgene Corporation
Total Payments
$45,347
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $45,347 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $45,347 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| NDS-CP-001 - A Multicenter, Open-Label Study to Estimate the Effect Sizes of HRCT Endpoints in Response to GLUCOCORTICOID Induction Therapy in Subjects With Pulmonary Sarcoidosis | Celgene Corporation | $45,347 | 0 |
Top Doctors Receiving Payments for Glucocorticoid
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Winston Salem, NC | $45,347 | 4 |
Ad
Manufacturing Companies
- Celgene Corporation $45,347
Product Information
- Type Drug
- Total Payments $45,347
- Total Doctors 0
- Transactions 4
About Glucocorticoid
Glucocorticoid is a drug associated with $45,347 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2018 to 2018. In 2018, $45,347 was paid across 4 transactions to 0 doctors.
The most common payment nature for Glucocorticoid is "Unspecified" ($45,347, 100.0% of total).
Glucocorticoid is associated with 1 research study, including "NDS-CP-001 - A Multicenter, Open-Label Study to Estimate the Effect Sizes of HRCT Endpoints in Response to GLUCOCORTICOID Induction Therapy in Subjects With Pulmonary Sarcoidosis" ($45,347).